Background The epilepsies are a clinically heterogeneous group of neurological disorders. Despite strong evidence for heritability, genome-wide association studies have had little success in identifi cation of risk loci associated with epilepsy, probably because of relatively small sample sizes and insuffi cient power. We aimed to identify risk loci through meta-analyses of genome-wide association studies for all epilepsy and the two largest clinical subtypes (genetic generalised epilepsy and focal epilepsy).
Introduction
Epilepsy is a common disorder, aff ecting up to 4% of people at some time in life. 1 The disorder includes a group of heterogeneous syndromes defi ned by clinical, electroencephalographic (EEG), and brain imaging criteria. 2 Broadly, the epilepsies are divided clinically into generalised and focal forms. Genetic factors contribute to both, as shown by fi ndings from familial aggregation and twin studies. 3 Causative mutations in many genes, including some genes coding for ion channel subunits and others involved in synaptic function or brain development, have been reported. 3, 4 Most of these fi ndings were reported in patients with fairly rare familial epilepsies segregating in a Mendelian way or epilepsies arising from de-novo mutations (particularly in patients with severe infantile epilepsies). [5] [6] [7] The genetic determinants underlying the common epilepsies, for which clinical genetic data suggest complex inheritance, remain largely unknown. Some evidence suggests a role for rare sequence and copy number variants, [8] [9] [10] whereas the contribution of common polymorphisms is still unclear, 11, 12 partly as a result of the relatively small sample sizes analysed to date.
Findings from the largest genome-wide association study (GWAS) in epilepsy so far, including 3445 patients with focal epilepsy, 13 showed no variants of genomewide signifi cance. More recently, fi ndings from a study of 1018 patients with mesial temporal lobe epilepsy with hippocampal sclerosis (a subtype of focal epilepsy) implicated the 2q24.3 region around the gene encoding the sodium channel SCN1A, 14 and fi ndings from an independent study of Han Chinese patients with known or suspected lesional focal epilepsy showed evidence for a risk allele at 1q32 on the basis of a discovery sample of 504 cases. 15 For generalised epilepsy, a GWAS included 1527 European patients with genetic generalised epilepsies in the discovery analysis and 1493 patients in the replication cohort; investigators reported evidence for common risk alleles at 2p16.1 and 17q21.32, and suggestive evidence at the SCN1A locus. 16 Additionally, associations were reported for the juvenile myoclonic subtype of genetic generalised epilepsy at 1q43 and for absence epilepsy at 2q22.3. 16 In a large multicentre collaboration, we undertook a meta-analysis to detect variants that could increase risk for common epilepsies. In view of clinical evidence that some genetic factors might increase risk for epilepsy broadly and in a syndrome-specifi c manner, [17] [18] [19] we prespecifi ed three analyses as part of the study. Variants were sought that aff ected risk for all epilepsies, genetic generalised epilepsy (previously known as idiopathic generalised epilepsy), 2, 20 or focal epilepsy.
Methods

Study design and participants
We did a meta-analysis of data from 12 previously published or unpublished genetic cohort studies from EPICURE, 16 EPIGEN, 13 Philadelphia (PA, USA), the Imperial-Liverpool-Melbourne Collaboration, 21 GenEpa, 13 and Hong Kong (China) 15 (appendix). We identifi ed these studies from the scientifi c literature (through searches of PubMed in December, 2011, with the terms "epilepsy", "seizures", and "association studies"), through publicity via Chapters of the International League Against Epilepsy, and during international conferences. All participants in these 12 case cohorts (and their associated controls) were of European, Asian, or African ancestry (table 1, appendix).
The genetic cohort studies used a combination of population-based datasets as controls. These control cohorts were either screened or unscreened by questionnaire for neurological disorders (table 1, appendix).
All study participants provided written informed consent for DNA analysis. Local institutional review boards reviewed and approved study protocols at each site.
Procedures
We classifi ed seizures and epilepsy syndromes according to the International League Against Epilepsy terminology. 2, 20 For all cases, epilepsy specialists assessed phenotype at the source centre. Patients with epilepsy were assigned to one of three phenotypic categories: genetic generalised epilepsy, focal epilepsy, or unclassifi ed epilepsy.
Criteria for genetic generalised epilepsy were tonicclonic, absence, or myoclonic seizures with generalised spike-wave discharges on EEG and no evidence of an acquired cause. In rare instances the criterion for a diagnostic EEG was waived when clear clinical evidence suggested myoclonic or absence seizures with tonic-clonic seizures, and no evidence for an acquired cause. The International League Against Epilepsy has adopted the term genetic generalised epilepsy for syndromes previously known as idiopathic or primary generalised epilepsies, in view of strong evidence for a genetic basis from genetic epidemiological and twin studies and an absence of identifi ed acquired factors. 2, 20 In the phenotypic category of focal epilepsy, we included patients with a confi rmed diagnosis of focal epilepsy, including cases with focal structural brain lesions. These cases were predominantly adults, and as such, cases of benign epilepsy of childhood with centrotemporal spikes were not specifi cally included.
Unclassifi ed epilepsy consisted of patients in whom there was neither electroclinical evidence for generalised epilepsy nor evidence for a focal seizure onset. Additionally, cases with evidence for both generalised and focal epilepsy were included here.
The phenotyping committee curated patient phenotypes into a single database. Details relating to individual case cohorts are provided in the appendix. Analyses were done for three phenotypic groups: genetic generalised epilepsy, focal epilepsy, and all epilepsy (consisting of all patients with a confi rmed diagnosis of epilepsy, including genetic generalised epilepsy, focal epilepsy, and unclassifi ed epilepsy).
Statistical analysis
We used prespecifi ed criteria for quality control to fi lter cases and controls from the 12 cohorts (appendix). Because contributing sites had used diff erent genotyping platforms, we did imputation to infer genotypes for common genetic variants that were not directly genotyped, allowing us to combine results across sites. Each of the fi ve sites imputed their study datasets 22 This analysis uses linear regression, including a polygenic term designed to account for the contributions of population stratifi cation and causal variants aside from the one being tested. Although we were assessing a binary trait, we used linear regression (rather than logistic regression) because we expected eff ect sizes to be small. We did this analysis separately for each of the preselected phenotypic categories of epilepsy (all epilepsy, genetic generalised epilepsy, and focal epilepsy). Sex was included as a covariate.
We did a fi xed-eff ects meta-analysis with METAL (version generic-metal-2011-03-25). 23 Because almost all epilepsy cases were of European descent (table 1) , we chose a fi xedeff ects model to optimise power. Single nucleotide polymorphisms showing signifi cant amounts of heterogeneity (p<0·05) were removed before application of the fi xed-eff ects analysis. We applied genomic correction to the association analysis results for each dataset before combining for meta-analysis. These steps were done separately for each of the three phenotypic tests.
We set our genome-wide threshold for statistical signifi cance at 1·66 × 10 -⁸, representing an empirical Bonferroni correction of the 5 × 10 -⁸ genome-wide signifi cance threshold for three tests. We regarded signals with p values between 1·66 × 10 -⁸ and 5 × 10 -⁷ as suggestive evidence of association.
We calculated the proportion of phenotypic variance a variant must explain (heritability) for the detection power to be at least 80%. We used variance explained on the liability scale, 24 for which we assumed a point prevalence of 0·5% for all epilepsy, 0·2% for genetic generalised epilepsy, and 0·3% for focal epilepsy. 25 The required heritability was 0·07% or greater for all epilepsy, 0·17% or greater for genetic generalised epilepsy, and 0·10% or greater for focal epilepsy (appendix).
In addition to the main association analysis, we did logistic regression for variants in a 1 megabase window centred on each variant that showed suggestive evidence of association (p<5 × 10 -⁷) from any of the three meta-analyses (all epilepsy, genetic generalised epilepsy, or focal epilepsy). The purpose of this analysis was technical validation and to estimate odds ratios (ORs). We analysed the dosage data, including sex and the fi rst 20 principal components, with PLINK (version 1.07), 26 and then combined the results from each site again with a fi xed-eff ect meta-analysis.
Conditional analysis was done with FaSTLMM (version 2.0) on variants in the same regions as those defi ned for the logistic regression. The purpose of the conditional analysis was to establish whether any other genetic variants in the region were associated with the disease phenotype, independent of the strongest signal from that region. We conditioned on the most signifi cant variants within each of the three regions. Sex was included as a covariate in the conditional analysis. We applied Bonferroni correction to control for multiple testing in the conditional analysis and set the threshold for signifi cance at 5 × 10 -⁶ (each 1 megabase region contained approximately 10 000 single nucleotide polymorphisms).
To assess the accuracy of the imputation across regions showing signals satisfying genome-wide signifi cance, we did genotyping in a subset of patients included in the meta-analysis and compared hard genotypes with imputation dosage fi les. We selected a subset of individuals to represent each of the three broad ethnic origins included in our analysis (ie, European ancestry, African-American, and Asian). Genotyping was done with TaqMan (Life Technologies, Carlsbad, CA, USA) for rs28498976, Sanger sequencing for rs6732655, and Kasper KASP (LGC Genomics, Hoddesdon, Hertfordshire, UK) for rs2947349 (appendix), because diff erences in sequence context required specifi c genotyping platforms for each single nucleotide polymorphism.
We did enrichment analysis with the interval-based enrichment analysis tool as integrated in the package INRICH (version 1.0). 27 Briefl y, INRICH takes a set of independent, nominally associated genomic intervals and tests for enrichment of predefi ned gene sets with permutation. We analysed variants with p values less than 1 × 10 -⁵ and defi ned the interval around index single nucleotide polymorphisms with an r² threshold of 0·2. Gene sets as defi ned by gene ontology pathways were tested for enrichment.
Role of the funding source
The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The members of the strategy and analysis committees of the International League Against Epilepsy Consortium on Complex Epilepsies had full access to all data in the study. The strategy committee (appendix) of the Consortium takes fi nal responsibility for the decision to submit for publication.
Results
40 789 participants, comprising 10 064 people with epilepsy from 12 cohorts and 30 725 controls, were studied. After application of our quality control criteria (appendix), we included a total of 34 853 individuals (8696 with epilepsy and 26 157 controls) in the meta-analysis for all epilepsies (table 1) .
Principal component analysis suggested that the cohorts clustered in three broad ethnic origins (European, Asian, and admixed African-American), as expected (appendix). We noted an infl ation factor of 1·031, suggesting adequate control for possible cryptic stratifi cation (appendix).
In the all-epilepsy analysis, we identifi ed two loci with genome-wide signifi cance (p<1·66 × 10 -⁸; fi gure 1). The fi rst signal was located at 2q24.3 (fi gure 2). This signal was centred on the voltage-gated sodium channel gene SCN1A, which is a known gene associated with some monogenic epilepsies. 7, 28, 29 The most strongly associated variant in this interval was rs6732655 (p=8·71 × 10 -¹⁰, OR 0·89, 95% CI 0·86-0·93; table 2, appendix), located in intron 16 of SCN1A. Seventy other variants in this region satisfi ed the threshold for genome-wide signifi cance. Logistic regression validated the association with 2q24.3 (appendix). The direction of eff ect was consistent across most cohorts, and there was no evidence of substantial heterogeneity.
In view of the extent of linkage disequilibrium between the variants associated with all epilepsy in the 2q24.3 region (fi gure 2), we did logistic regression conditioned on the most signifi cant variant identifi ed from the univariate analysis (rs6732655). Our results suggested a tentative independent signal, coming from rs13406236, in an intronic variant in SCN9A (p=1·39 × 10 -⁴ on conditioning; appendix). We did not identify any further signifi cant signals.
A second signal for the all-epilepsy phenotype was located at 4p15.1 and included the 3 end of the protocadherin gene, PCDH7 (fi gure 3). The most strongly associated variant in this region was rs28498976 (p=5·44 × 10 -⁹, OR 0·90, 95% CI 0·87-0·94; table 2), located 2·5 kilobases from the 3 end of PCDH7. Logistic regression across PCDH7 supported the association with 7  4  3  6  5  2  8  1  15  12  11  14  13  10  16  9  2 2  19  18  21  20  17 X Chromosome this locus (appendix). We noted no additional signifi cant signals from 4p15.1 on conditioning for rs28498976 (appendix). The direction of eff ect was consistent across all cohorts and we noted no evidence of heterogeneity. Although achieving genome-wide signi fi cance only for the all-epilepsy phenotype, the PCDH7 signal seemed stronger in genetic generalised epilepsy than in focal epilepsy (appendix).
PCDH7 encodes a calcium-dependent adhesion protein, not previously associated with epilepsy. It is a member of the cadherin gene family. The gene is expressed in the CNS, specifi cally in thalamocortical circuits and the hippocampus, 30, 31 and expression of PCDH7 is controlled by MECP2, 32 mutations in which cause Rett syndrome. The cytoplasmic domain of the PCDH7 protein binds to protein phosphatase 1α (PPP1CA), which is enriched in dendritic spines and is important in learning and memory, 33 and to template activation factor 1 (TAF1), which along with PCDH7 is involved in neurite extension. 34, 35 Suggestive signals of note (p<5 × 10 -⁷) for the all-epilepsy phenotype were detected at 3q26.2 (p=4·42 × 10 -⁷) and 4p12 (p=1·71 × 10 -⁷; table 2). The 3q26.2 region contained the 5 end of GOLIM4 (appendix). This gene encodes Golgi internal membrane protein 4, which is degraded when manganese increases above normal concentrations, suggesting a role for this protein in manganese homoeostasis. 36 Almost all brain manganese is bound to glutamine synthetase, an enzyme playing a key part in production or degradation of the neurotransmitters glutamate, glutamine, and GABA. Decreased brain glutamine synthetase and manganese concentrations have been reported in epilepsy. 37, 38 The 4p12 region contained the 3 end of the GABA receptor, α2-subunit gene (GABRA2). Mutations in other GABA receptors have been reported to cause epilepsy. 39 After quality control, we included 21 596 individuals (2606 cases and 18 990 controls) across eight cohorts in the meta-analysis of genetic generalised epilepsy (table 1), a subset of those included in the all-epilepsy analysis. Results from the genetic generalised epilepsy metaanalysis suggested an infl ation factor of 1·05 (appendix).
A single signal achieved the threshold of genome-wide signifi cance (fi gure 1). Located at 2p16.1, the interval contained genes encoding vaccinia-related kinase 2 (VRK2) and Fanconi anaemia, complementation group L (FANCL; fi gure 4). The most strongly associated variant in this region was the intergenic variant rs2947349 (p=9·99 × 10 -⁹, OR 1·23, 95% CI 1·16-1·31; table 2). Logistic regression analysis supported the association with 2p16.1 (appendix). We noted no additional signifi cant signals from 2p16.1 on conditioning for rs2947349 (appendix). The direction of eff ect was consistent across all cohorts, and the association seemed to be specifi c to genetic generalised epilepsy (appendix).
VRK2 is a serine-threonine protein kinase involved in signal transduction and apoptosis. 40, 41 Variation in VRK2 has previously been suggested as a risk factor for epilepsy 16 and schizophrenia. [42] [43] [44] Indeed, the schizophreniaassociated risk variant (rs2312147) 43 shows also a strong signal for genetic generalised epilepsy (p=2·3 × 10 -⁶, OR 1·22, 95% CI 1·14-1·30) and is in high linkage disequilibrium with the strongest variant for genetic generalised epilepsy (r²=0·82), although the direction of the eff ect is opposite (ie, the protective variant for epilepsy raises risk for schizophrenia). The EPICURE cohort, in which 2p16.1 was originally proposed as a risk factor for genetic generalised epilepsy, was included in our metaanalysis. After exclusion of the EPICURE cohort, the top single nucleotide polymorphism from their study (rs13026414) 16 remained nominally signifi cant at p=7 × 10 -³ here. These results provide further support to the suggestion that VRK2 is a risk locus for both epilepsy and schizophrenia. The other gene in the region, FANCL, codes for a RING-type E3 ubiquitin ligase of the Fanconi anaemia pathway. FANCL mono-ubiquitinates FANCD2 and FANCI, proteins involved in DNA repair and homologous recombination. 45 FANCL has not been previously implicated in epilepsy or any seizure-related phenotype.
We detected suggestive evidence for association with genetic generalised epilepsy at 4p15.1 (p=1·87 × 10 -⁷), 5q22.3 (p=6·34 × 10 -⁸), and 11q22.2 (p=2·37 × 10 -⁸; table 2). The 4p15.1 PCDH7 signal was the same as that with genomewide signifi cance for the all-epilepsy phenotype (fi gure 3, appendix). The 5q22.3 signal was intergenic (appendix). The 11q22.2 signal contained the 5 end of the matrix metallopeptidase gene MMP8 (appendix). The direction of eff ect was consistent across all cohorts and seemed specifi c to genetic generalised epilepsy (appendix). With a p value of 2·37 × 10 -⁸, the 11q22.2 signal reached the conventional threshold for genome-wide signifi cance (p<5 × 10 -⁸), but not our more stringent value (p<1·66 × 10 -⁸). Matrix metallopeptidases are zinc-dependent endopeptidases involved in the breakdown of the extracellular matrix in physiological processes and in blood-brain infl ammation. 46 Increased expression of MMPs has been recorded in various neurological disease states, 47 and epileptogenesis is decreased in MMP9 knockout mice but increased in transgenic rats overexpressing MMP9. 48 After quality control, we included 28 916 individuals (5310 cases and 23 606 controls) from ten cohorts in our meta-analysis of focal epilepsy. No signal achieved genome-wide signifi cance. Results from the focal metaanalysis suggested an infl ation factor of 1·014 (appendix). We observed one notable subthreshold signal (rs12987787, p=1·45 × 10 -⁷) from 2q24.3, the region containing SCN1A (appendix).
Targeted genotyping of the three GWAS-signifi cant signals supported the accuracy of imputation, with a minimum correlation of 0·98 noted between experimentally determined and imputed genotypes (appendix).
Assessment of enrichment of gene ontology terms for regions containing variants with nominally signifi cant p values (p<1 × 10 -⁵) for each of the three phenotypes showed enrichment in several signalling pathways (appendix). Although none of these variants remained signifi cant after correction for multiple testing, our results suggest pathways with biological plausibility.
Finally, we investigated whether any of the four susceptibility loci at nominal genome-wide signifi cance (p<5 × 10 -⁸) were associated with outcome of newly treated epilepsy with use of data from Speed and colleagues. 21 We used both the index single nucleotide polymorphism (table 2) VRK2→ ←FANCL appendix). The minimum p value of association with outcome of newly treated epilepsy for any susceptibility locus was 8·14 × 10 -⁴ (MMP8). We noted no evidence for an association between SCN1A (the gene that codes for the target of sodium-channel-blocking class antiepileptic drugs) and epilepsy outcome.
Discussion
In this genome-wide association meta-analysis of epilepsy and its most common subtypes, we identifi ed three loci with genome-wide signifi cance, and our fi ndings suggest that some loci might be specifi cally associated with an epilepsy type.
In the whole cohort consisting of all epilepsy, the region of the sodium channel subunit gene SCN1A was clearly associated with the disease. This gene is a wellestablished cause of genetic epilepsy with febrile seizures plus (GEFS+), 28, 29 a generally mild, familial form of epilepsy, and with Dravet syndrome, a severe epileptic encephalopathy usually arising from de-novo mutations. 7 SCN1A was associated with mesial temporal lobe epilepsy and hippocampal sclerosis with febrile seizures in a recent GWAS 14 and in a meta-analysis of SCN1A rs3812718. 49 SCN1A mutations have also been reported in a range of paroxysmal neurological disorders including familial hemiplegic migraine 50 and, more rarely, in some focal epilepsies. 51 Whether this robust association with all epilepsy is a true common variant association or a synthetic association due to tagged rare variants in cases with GEFS+ is therefore not clear. Although the cohorts might have included individuals from monogenic GEFS+ families with SCN1A mutations of large eff ect, review of the phenotyping data suggested that inclusion of more than a few such cases was unlikely; moreover, SCN1A variants have been reported only in about 10% of large GEFS+ families. 52 Our all-epilepsy analysis identifi ed a second locus (4p15.1) that satisfi ed our threshold for genome-wide signifi cance. This locus is newly associated with epilepsy and implicates the gene PCDH7. This protocadherin gene is a plausible candidate for common forms of epilepsy, as mutations in another protocadherin gene, PCDH19, cause epilepsy and mental retardation in female patients. 53 For the specifi c category of genetic generalised epilepsy, we noted the association at 2p16.1 that was previously reported in the EPICURE cohort; 16 this cohort provided about half of our sample for the meta-analysis of this subtype (table 1) . The association maintained nominal signifi cance after removal of EPICURE cases for this locus, where the genes VRK2 and FANCL are within close proximity. With our additional samples, we did not note signifi cance for the 17q21 locus reported by EPICURE investigators for genetic generalised epilepsy (appendix).
For the subcategory of focal epilepsy, we did not note any locus with genome-wide signifi cance, consistent with negative fi ndings from the EPIGEN study of focal epilepsy (samples from which were included in our analysis). 13 However, a signal at 2q24.3 (containing SCN1A) in focal epilepsy approached but did not achieve signifi cance (appendix). This signal in focal epilepsy was in high linkage disequilibrium with that noted for all epilepsy (r²=0·85). Importantly, the 2q24.3 signal for focal epilepsy that we recorded diff ered to that reported in a recent study of the narrow focal epilepsy phenotype of mesial temporal lobe epilepsy and hippocampal sclerosis with febrile seizures. 14 rs7587026 (the previously reported variant) was not signifi cant in our analysis of a broader focal epilepsy phenotype consisting of all focal epilepsies (p=0·01; appendix). We also did not note the association at 1q32.1 (implicating CAMSAP1L1) that was previously reported in the Hong Kong cohort, 15 which was included in our sample (appendix). Most patients in this cohort had focal epilepsy due to known lesions.
Consistent with experience of GWAS in other neuropsychiatric disorders, and common disorders in general, this study reinforces the value of large sample sizes. In the epilepsies, electroclinical and imaging data allow the identifi cation of clinical syndromes that share common clinical features. Our study fi ndings suggest that an experimental design that includes fractionation of samples into clinical subtypes can reveal syndrome-specifi c risk alleles, but the identifi cation of these alleles will be assisted by the collection and genotyping of larger sample sizes. Although this lumping versus splitting debate in genetic analyses is not unique to the epilepsies, there has been longstanding controversy about it in clinical epileptology, 54 which genetics will help to inform.
Limitations of our study include sample size; although ours is large, even larger samples have yielded more fi ndings in other disorders. [55] [56] [57] Larger samples would enable further analysis of epilepsy subtypes, and the International League Against Epilepsy Consortium on Complex Epilepsies now provides a useful vehicle for future eff orts. Second, our meta-analysis relied on genotypes generated separately on various platforms, an issue common to most meta-analyses. Third, extension of the phenotyping data to include treatment outcome would be ideal, but in a cross-sectional cohort this approach has methodological diffi culties. Finally, we did not have an independent replication sample. However, stringent criteria for statistical signifi cance were set a priori, and for loci achieving our threshold of genomewide signifi cance the direction of eff ects were largely consistent across the cohorts, and extended over multiple variants in high linkage disequilibrium.
Taken together, these data show that, with suffi cient sample size, susceptibility loci for common epilepsies can be identifi ed through the analysis of common variation. The role of rare variants of large eff ect is also well established, particularly in rarer Mendelian epilepsies. [3] [4] [5] [6] [7] The role of rare variants in the common epilepsies is at present under exploration by deepsequencing approaches. 11, 58, 59 A dual approach of identifi cation of both rare and common variation will result in improved understanding of the genetic architecture for the overall population of people with epilepsy, necessary for precision medicine. Although our fi ndings will not be of immediate clinical usefulness, they are an important fi rst step to understand the genetic architecture of the epilepsies, which could lead to clinically relevant markers of prognosis and outcome. 
